Subsequently, the phase 3 NALA study compared neratinib-capecitabine to lapatinib-capecitabine in metastatic HER2+ breast cancer in patients who had progressed on two or more HER2+ directed therapies [24]. This evidence concerns the gene ERBB2 and breast carcinoma.